 |
|
Cytokine Milieu in Psoriasis and Cardiovascular Disease May Explain the Epidemiological Findings Relating These 2 Diseases
Srdjan Prodanovich, MD;
Michael L. Shelling, MD;
Daniel G. Federman, MD;
Robert S. Kirsner, MD, PhD
Arch Dermatol. 2008;144(11):1518-1519.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
Interleukin-12, Interleukin-23, and Psoriasis: Current Prospects
Torti DC, Feldman SR
J Am Acad Dermatol. 2007;57(6):1059-1068
The clinical phenotype of psoriasis results from infiltration of T cells in the skin and elaboration of inflammatory cytokines. Interleukin (IL)-12 and, more recently, IL-23 have been implicated in the pathogenesis of psoriatic lesions. New therapies, including a monoclonal antibody against a subunit shared by IL-12 and IL-23, have been developed to treat psoriasis. Our purpose was to review the literature on IL-12 and IL-23 as a basis for understanding the use of anti-IL-12/IL-23 therapy for psoriasis. A review of English-language articles was performed using PubMed to identify articles pertaining to IL-12, IL-23, and psoriasis. IL-12 and IL-23 share a common subunit (p40) and have a distinct subunit (p35 and p19, respectively). Transgenic mice that overexpress IL-12 p40 . . . [Full Text of this Article]
COMMENT
AUTHOR INFORMATION
Departments of Dermatology and Cutaneous Surgery (Drs Prodanovich, Shelling, and Kirsner) and Epidemiology and Public Healing (Dr Kirsner), University of Miami Miller School of Medicine, Miami, Florida; and Department of Medicine, Veterans Administration Medical Center (Dr Federman), and Department of Internal Medicine, Yale University School of Medicine (Dr Federman), West Haven, Connecticut
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
